LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Destiny Pharma Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 29.80 241,988 16:22:36
Bid Price Offer Price High Price Low Price Open Price
29.60 30.00 29.80 29.60 29.80
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceutical Preparations 0.00 -6.50 - - 28.15
Last Trade Time Trade Type Trade Size Trade Price Currency
16:26:19 O 27,119 29.50 GBX

Destiny Pharma (DEST) Latest News

Destiny Pharma (DEST) Discussions and Chat

Destiny Pharma Forums and Chat

Date Time Title Posts
31/5/202316:13Destiny Pharma plc1,550
22/11/202212:29Destiny Pharma1

Add a New Thread

Destiny Pharma (DEST) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-06-01 16:22:4029.5027,1198,000.11O
2023-06-01 15:26:2029.4710,1943,004.17O
2023-06-01 15:24:2929.5010,1833,003.99O
2023-06-01 15:22:3730.005015.00O
2023-06-01 14:42:4629.951,000299.50O

Destiny Pharma (DEST) Top Chat Posts

Top Posts
Posted at 02/5/2023 16:28 by eva_1989
Sold half of my holding with breakeven

keeping £50K worth now

Sell 14,711 @ GBP0.3413 Destiny Pharma Plc
£5,000.13 £236,491.51
Sell 14,711 @ GBP0.3413 Destiny Pharma Plc
£5,000.13 £231,491.38
Sell 29,455 @ GBP0.3401 Destiny Pharma Plc
£9,998.03 £226,491.25
Sell 49,660 @ GBP0.3428 Destiny Pharma Plc
£17,000.01 £216,493.22
Sell 40,932 @ GBP0.3426 Destiny Pharma Plc
£14,000.26 £199,493.21

I'm just not happy with few things i mentioned earlier and wanted to trimmed down position rather than add here

i will buy if i show management also buying else happy to wait with whatever holding I've

with my less holding, i will cry less here.

But what a mess this management has made to this share

2 P3 product ready to go and still share price is at all time low.

logic says to buy here but with this share and management, logic just doesn't work

catch you later

Posted at 02/5/2023 10:26 by sev22
Introduction to morning note from House broker finnCap:


CORP SPOR-COV update – supportive of clinical development.

Destiny Pharma and its partner, SporeGen, announced positive results from testing SPOR-COV in several COVID-19 and influenza research models, which support the ongoing development of SPOR-COV as a prophylactic (preventative) nasal spray for COVID-19, influenza and potentially other similar respiratory viral infections – the intention is to find further partners to continue the development and commercialisation. Whilst early stage, these data build out Destiny’s pipeline further. We consider Destiny to be a significantly derisked equity story following the Sebela $570m bio-dollar deal for NTCD-M3 (prevention of recurrent C. difficile infection) and strengthened balance sheet, which provides a runway into H2 2024. Together with the prospect of partnering XF-73, we leave forecasts unchanged and reiterate our 285p price target.

Posted at 18/4/2023 13:07 by s34icknote
Does make you wonder where the share price would be without our distressed seller !!!!
Posted at 04/4/2023 08:10 by sicilian_kan
Yet more good news published on NTCD-M3. So Destiny has world leading, best in class data in P2. The P3 is fully funded by a partner, in a deal worth up to $570m in milestones with tiered, double-digit royalties. Destiny retains a majority of all non-US rights, so further M3 deals are possible. There is £7m in cash.

And this is:

(a) despite M3 having been brought in as a backup to derisk Destiny's pipeline, with the main drug also due to partner for P3 this year in an even bigger market and with an up front likely; and

(b) with Destiny having only acquired M3 around 3 years before for just £2m. To turn that in such a short period of time into a deal worth $570m in milestones and tiered double digit royalties with majority non-US rights retained is remarkable and demonstrates with external validation the judgment of the board, the commerciality of Destiny's pipeline and their deal making ability. I note too the background of Neil Clark, who was involved in both CeNeS and Ergomed, the former was sold and the latter has become a very successful company.

Meanwhilst, some posters on here ignore the above and choose to focus on:

1. Suggesting an 80% collapse in share price on open on the day an excellent RNS comes out validating M3 with a further antibiotic now added to US guidelines.

2. Criticising a poster for not being here enough.

3. Blaming others for having not invested at the bottom, despite everything suggesting (see above) that Destiny is heading in the right direction and that given time things will turn.

Posted at 06/3/2023 15:58 by smithie6
what do ppl think

1) is the big fall from 55p to 35p a red flag, to avoid the shares ?

2) the share price has fallen due to collaboration deal combined with a fair % of dilution due to cash raise.
The share price is at ~ a medium term low.

3) the stage 3 trial for the collaboration for the drug to resist/treat CDificile does not start until 2024

4) the advance payment for the collaboration was only 1 million. imo a small amount & hence a dilutive cash raise needed to be created

5) the % royalty of the development partner for sales outside north America is not revealed.
it reduces the % for DEST.

6) the share price has struggled to stay as high as the placing price for new shares....inferring that shareholders are not enthused.


Can someone put a glossy spin on the above 'cause where I am looking from I struggle to be enthused by these points.

Posted at 27/2/2023 16:12 by eva_1989
Yes agree.

What’s the point of fund raise every year ( or other year )

I just never understand.

See how share price collapsed

Anyway - guess this year now exciting news should be XF deal. That should push share price higher but I wouldn’t trust those crazy high target price from the brokers..

Posted at 27/2/2023 08:13 by sev22
Here is the introduction to FinnCap's broker note this morning:

NTCD-M3 US partnering deal and fundraise: value inflection.

Destiny Pharma has announced a US partnering deal for the Phase III development and commercialisation of NTCD-M3 for the prevention of the recurrence of Clostridioides difficile infection. Destiny Pharma gains upfront and milestone payments of up to US$570m and royalties on sales of 10-18% on a tiered basis. The deal is predicated on Destiny strengthening its balance sheet and it plans to raise £7m via a Placing and up to £1m in an Open Offer. The deal de-risks the R&D pipeline and the Destiny Pharma equity story, especially with the prospect of partnering deals on NTCD-M3 (ex-US) and XF-73. We introduce 2023E and 2024E forecasts and reduce our riskadjusted DCF target price from 306p to 285p, given the higher share count.

- NTCD-M3 US Partnering deal. Destiny Pharma has announced a partnering deal for the Phase III development, registration and marketing of NTCD-M3 in the US with Sebela Pharmaceuticals, a GI-focused pharma PE-backed company with a strong track record of growing revenues and profitability. Destiny will gain US$20m in upfront and near-term milestone payments, up to US$550m in sales-based milestone payments and 10-18% royalties on end-market sales. Sebela will incur all Phase III, registration and marketing costs. The Group had announced close to the end of 2022 that it expected to sign a partnering deal in early 2023 and so has delivered it.

- Associated fundraise. The US deal with Sebela is dependent on Destiny strengthening its balance sheet and as such, Destiny plans to launch a Placing and Open Offer to raise up to £8m. The additional capital will allow Destiny to progress other programmes such as XF-73 more quickly. Destiny has re-iterated it plans to sign a partnering deal for the Phase III development and commercialisation of XF-73 in 2023, which could be another value inflection point.

- De-risking R&D pipeline and equity story. While our forecasts included an assumption of a partnering deal for NTCD-M3 (although on slightly different terms), that Destiny has concluded such a deal, validates the NTCD-M3 development programme, removes the need for Destiny to fund expensive Phase II trials, de-risks the R&D pipeline and de-risks the overall equity story for Destiny Pharma. As such, with the prospect of further partnering deal possible in 2023 and in 2024, the shares have several further potential catalysts.

- Valuation and forecasts. We introduce 2023E and 2024E forecasts; there are minimal changes to our 2022E forecasts. Destiny has noted that the signing of the Sebela deal and associated fundraise would provide a cash runway until late-2024. As we expect further partnering deals on XF-73 (potentially in 2023) and NTCD-M3 ex-US in 2024, we make the assumption that the Group will be funded beyond its guidance and include placeholder revenue in 2024 to that effect. Including the upfront payment from Sebela, the likely milestone payments and tiered royalties and assuming a £7m equity raise but with an increased share count, our risk-adjusted DCF target price reduces from 306p to 285p.

Posted at 14/2/2023 17:37 by eva1989
If i look at last couple of years fund raise, then they usually raise 6 months before. This year however that pattern break..

Per 08 September 2022 RNS

· Company funded through to mid-2023.

So technically now We've just over 4 months left before another fund raise:

Fund Raise - 9th Nov 2020

· The Issue Price represents a discount of approximately 4.7 per cent. to the 60-day volume weighted average price of 68.3 pence per Existing Ordinary Share (as at 6 November 2020), which reflects the strong momentum in the share price, that has risen over three-fold since late July.

Fund Raise - 8th March 2022 was a Shocker as it was 28% discounted

· The Issue Price represents a discount of approximately 28 per cent. to the closing mid-market price of 69 pence per existing Ordinary Share on 7 March 2022, being the latest practicable date prior to this Announcement.

Many here thinks that as Licensing deal is vvvv near - US Pharma could take care of the upfront cost and hence no fund raise.

Last few days/weeks share price movement have been very strange...

I've decent position but still believe Fund raise first and then licensing deal - I hope i am wrong here. I just dont want to remain out as risk reward is far much better...

Posted at 22/12/2022 09:13 by sev22
Introduction to research note from finnCap Group:

DESTINY PHARMA (DEST): CORP Trading update: NTCD-M3 partnership expected early in 2023 Destiny Pharma’s trading update notes that it is close to signing a US development and commercialisation agreement for Phase-III-ready lead asset NTCD-M3. It expects to announce the agreement, which it continues to finalise, in early 2023. It is reasonable, in our view, to expect a deal to include full funding for US Phase III development to come from the partner, with potential upfront/milestone/royalties on commercial sales to Destiny; Destiny would retain all ex-US rights (aside from rights in China and some Asian countries ex-Japan) to NTCD-M3 and Destiny could sign further partnering agreements for the development and commercialisation of NTCD-M3 outside those territories. The Group also expects to sign a partnering deal on its XF-73 nasal gel in 2023. Both deals could be transformative for Destiny Pharma, provide a boost to its balance sheet and greater certainty on the value of both of its two main late-stage development programmes. There are no changes to our forecasts or 306p target price.

Posted at 18/11/2022 19:28 by ttlance
SK, I would take their price target with a pinch of salt. They are after all the house broker and are paid handsomely by Destiny to promote the company. Regarding the confidence from the management, they have been confident of getting an immanent agreement for over a year now. Of course, they are going to come across positive when they talk about the company's prospects (no management talks their own business down), as long as Neil C receives his £200k per annum this will be the case. One thing to also note is that the potential partner will be aware that the business is running out of cash and will therefore use this to their advantage, ensuring the deal (if one is signed) will be greatly in their favour. If the management showed their worth, they would have raised enough funds, when the share price was much higher, with these funds lasting them a couple years. This would have put them in a much better position in terms of negotiations. The sole reason why the share price is at this level is due to lack of funds and also the continual delays, it has been stated that the potential launch of their earliest drug will be 2026...add a couple of years onto this for further delays. It wouldn't surprise me if the company went under and the assets picked up on the cheap.
Destiny Pharma share price data is direct from the London Stock Exchange
Your Recent History
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230602 05:34:08